Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 October 2019Website:
http://www.phathompharma.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 29 min agoDividend
Analysts recommendations
Institutional Ownership
PHAT Latest News
FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November and December:
FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, November 7, 2024, to report its third quarter 2024 financial results and provide a business update.
FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present data from multiple investigational studies for its first-in-class treatment VOQUEZNA® (vonoprazan) tablets at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting, being held October 25-30 in Philadelphia, PA. VOQUEZNA is approved for the relief of heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (Non-Erosive GERD), for the treatment of all severities of Erosive Esophagitis, commonly referred to as Erosive GERD, and relief of related heartburn, and in combination with antibiotics for the eradication of Helicobacter pylori (H. pylori) infection.1 VOQUEZNA is the first and only U.S. Food and Drug Administration (FDA)-approved potassium-competitive acid blocker (PCAB).2
NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary duty.
FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in September:
FLORHAM PARK, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten offering of 8,695,652 shares of its common stock and pre-funded warrants to purchase 2,608,922 shares of common stock. The shares of common stock are being sold at a price of $11.50 per share and the pre-funded warrants are being sold at a price of $11.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Phathom from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $130 million. The offering is expected to close on or about August 20, 2024, subject to satisfaction of customary closing conditions.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President and CEO Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial Officer Azmi Nabulsi - Chief Operating Officer Conference Call Participants Annabel Samimy - Stifel Joseph Stringer - Needham & Company Yatin Suneja - Guggenheim Paul Choi - Goldman Sachs Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Hello, and welcome to Phathom Pharmaceuticals Second Quarter 2024 Earnings Results Call.
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.25 per share versus the Zacks Consensus Estimate of a loss of $1.20. This compares to loss of $0.84 per share a year ago.
VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD) VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid reduction of heartburn with daily treatment VOQUEZNA represents the first major innovation in GERD treatment in over 30 years and the only FDA-approved treatment of its kind available in the U.S. A Media Snippet accompanying this announcement is available by clicking on this link. FLORHAM PARK, N.J.
Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its products due to the presence of a cancer-causing agent in commercial batches, but eventually received full FDA approval. PHAT aims to target a substantial market opportunity with Vonoprazan, potentially leading to a share price rally and challenging a billion-dollar market cap valuation.
- 1(current)
What type of business is Phathom Pharmaceuticals?
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing new treatments for gastrointestinal diseases. Its portfolio includes vonoprazan, a low molecular weight oral acid blocker, a potassium-competitive acid blocker that inhibits acid secretion in the stomach. Vonoprazan demonstrates rapid, potent, and durable antisecretory effects and has shown clinical benefits in the treatment of gastroesophageal reflux disease, as well as in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was registered in 2018 and is based in Buffalo Grove, Illinois.
What sector is Phathom Pharmaceuticals in?
Phathom Pharmaceuticals is in the Healthcare sector
What industry is Phathom Pharmaceuticals in?
Phathom Pharmaceuticals is in the Biotechnology industry
What country is Phathom Pharmaceuticals from?
Phathom Pharmaceuticals is headquartered in United States
When did Phathom Pharmaceuticals go public?
Phathom Pharmaceuticals initial public offering (IPO) was on 25 October 2019
What is Phathom Pharmaceuticals website?
https://www.phathompharma.com
Is Phathom Pharmaceuticals in the S&P 500?
No, Phathom Pharmaceuticals is not included in the S&P 500 index
Is Phathom Pharmaceuticals in the NASDAQ 100?
No, Phathom Pharmaceuticals is not included in the NASDAQ 100 index
Is Phathom Pharmaceuticals in the Dow Jones?
No, Phathom Pharmaceuticals is not included in the Dow Jones index
When was Phathom Pharmaceuticals the previous earnings report?
No data
When does Phathom Pharmaceuticals earnings report?
The next expected earnings date for Phathom Pharmaceuticals is 07 November 2024